Melanoma: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PD-1 54
• BRAF 18
• PD-L1 21
• MEK 7
• TP53 0
• CTLA-4 10
• MAPK 2
• NRAS 8
• STING 0
• STAT3 0
• PRAME 3
• AKT 0
• PI3K 0
• BAP1 2
• VEGF 4
• mTOR 0
• ERK 0
• LAG-3 2
• RAS 2
• CTNNB1 0
• CD40 0
• CDKN2A 3
• TNF 0
• YAP 0
• PTEN 1
• JAK 0
• KIT 3
• KRAS 1
• JNK 0
• PPAR 0
• TIGIT 0
• ALK 0
• B7-H3 3
• BCL-2 0
• EZH2 0
• HIF-1 0
• IL-15 1
• NF1 2
• NLRP3 0
• NRF2 0
• AMPK 0
• HSP90 0
• CD47 0
• MYC 0
• PKM2 0
• AXL 1
• COX-2 0
• EGFR 0
• GPX4 0
• MET 1
• HDAC 1
• IDH 1
• IL-17 1
• MMP-9 0
• CDK4/6 0
• CXCR4 0
• FGFR 0
• HER2 3
• IGF1R 0
• PSMA 3

16 of 16+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Validation of artificial intelligence-based minibinders and inhibitors of Midkine in immune resistant tumours (MDK_MINIBINDERS)

  Fundacion Sector Publico Estatal Centro Nacional Investigaciones Oncologicas Carlos Iii· Madrid, Spain· EU contribution €150,000· until Apr 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Light-triggered Ultra-precise Carbon-enhanced phycocyanin Engineered Needles for Therapy (LUCENT)

  Univerzita Palackeho V Olomouci· Olomouc, Czechia· EU contribution €191,918· until Aug 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeted therapy to block melanoma progression through peptide phage-display profiling of melanoma cells and derived extracellular vesicles (Target-MelaneX)

  I3s - Instituto de Investigacao e Inovacao Em Saude Da Universidade Do Porto· Porto, Portugal· EU contribution €207,183· until Aug 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC

  THz-FIR Colour Imaging of Skin Condition Based on Analysis of Its Thermal Emission (THz-Skin)

  Ita-Suomen Yliopisto· Kuopio, Finland· EU contribution €2,998,913· until Jan 2030· 5 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Capturing UV Sunlight Using Hydrogen-Bond Networks: Organic Sun Screens for Skin Protection (CUSHOSP)

  United Nations Educational Scientific and Cultural Organization· Paris, France· EU contribution €150,000· until Jun 2027· 2 countries

  The disease is named only in the funder's project summary, not in the title.

5 of 12 running projects, newest first. Listed amounts together: €11.7m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

  NCT02568267· Hoffmann-La Roche· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 51
• Organoids 8
• Mendelian Randomization Analysis 12
• CRISPR-Cas Systems 22
• Gene Expression Profiling 116
• Sequence Analysis, RNA 9
• Whole Genome Sequencing 6
• Exome Sequencing 7
• Proteomics 47
• Metabolomics 20
• Mass Spectrometry 10
• Flow Cytometry 65
• Immunohistochemistry 106
• Liquid Biopsy 12
• Circulating Tumor DNA 37
• Xenograft Model Antitumor Assays 121
• Positron-Emission Tomography 31
• Magnetic Resonance Imaging 57
• Machine Learning 49
• Deep Learning 44
• Cohort Studies 78
• Genome-Wide Association Study 22

• Cancer morbidity and mortality in individuals with obsessive-compulsive disorder: a population-based and sibling cohort study in Sweden and Denmark.

  BMC Med, Nov 2026

• A population-based cohort study of fracture risk among 122 255 adults before and after cancer diagnosis compared with matched controls.

  J Bone Miner Res, Oct 2026

• Biopsy Type and Metastatic Recurrence in Melanoma: A Cohort Study.

  J Drugs Dermatol, Oct 2026

• Skin cancer mortality in Australian and New Zealand kidney transplant recipients: a population-based cohort study using linked health data, 1990-2019.

  Br J Dermatol, Sept 2026

• Beta Testing an mHealth Symptom Management Intervention for People With Advanced Cancer: Single-Cohort Feasibility and Acceptability Study.

  JMIR Cancer, Sept 2026

• Profiling immune check point inhibitors - Induced arthritis: A systematic review and pooled analyses of cohort studies.

  J Autoimmun, Sept 2026

• BRIDGE-KO: auditable transfer learning with bridged knockoffs improves cross-cohort microbiome prediction of immunotherapy response.

  Brief Bioinform, Sept 2026

• Risk of subsequent primary melanoma in 68 002 five-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup cohort study.

  J Natl Cancer Inst, Sept 2026

• [99mTc]Tc-Tilmanocept sentinel node biopsy and long-term outcomes in melanoma: A cohort study and literature review.

  Eur J Surg Oncol, Aug 2026

• De Novo Cancer in Liver Transplant Patients With HIV Infection: A Multicenter Nationwide Cohort Study.

  Clin Infect Dis, Jul 2026

See which targets of this disease your abstract mentions, and go to the people working on them.